SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of “Moderate Buy” from Analysts

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a consensus rating of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $10.00.

A number of brokerages recently commented on SABS. Chardan Capital reiterated a “buy” rating and set a $12.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, December 18th. Guggenheim began coverage on SAB Biotherapeutics in a report on Friday, December 19th. They set a “buy” rating and a $15.00 price target for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, UBS Group began coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $7.00 target price for the company.

SAB Biotherapeutics Stock Down 6.6%

Shares of NASDAQ:SABS opened at $3.85 on Tuesday. The firm’s 50 day moving average price is $3.97 and its 200 day moving average price is $3.14. The stock has a market cap of $183.30 million, a price-to-earnings ratio of -1.25 and a beta of 0.58. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.38. As a group, equities research analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new position in SAB Biotherapeutics in the third quarter valued at $22,954,000. Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth about $8,847,000. RA Capital Management L.P. purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at about $8,847,000. Woodline Partners LP acquired a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at about $5,730,000. Finally, Spruce Street Capital LP acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at about $8,222,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.